Cargando…
Loading, please waitCargando…
Loading, please waitConditions
Androgenetic alopecia is the most common cause of progressive hair loss in men and women. Below we explain how it develops, what regenerative therapies can realistically offer, and how our physicians at Regeneris build a plan around your specific pattern of thinning.
Androgenetic alopecia is a genetically determined, hormone-mediated condition in which scalp hair follicles become progressively miniaturized. Instead of producing thick, pigmented terminal hairs, affected follicles cycle into thinner, shorter and less pigmented strands until they remain dormant for prolonged periods. It is not a sudden loss — it is a slow replacement of healthy hair by weaker hair, often noticed only when overall density has already changed.
The biological driver is dihydrotestosterone (DHT), a hormone produced when testosterone is converted by the enzyme 5-alpha reductase. In scalp areas that are genetically sensitive to DHT, the hormone binds to androgen receptors in the dermal papilla, shortens the growth (anagen) phase of the hair cycle and triggers progressive miniaturization. Areas like the back and sides of the scalp are typically resistant to DHT, which is why they remain stable even in advanced cases.
Inheritance is polygenic. Multiple genes from both sides of the family influence androgen receptor density, sensitivity and the local enzymatic environment in the scalp — so the old idea that hair loss only comes from the mother's father is biologically inaccurate. Other factors such as chronic scalp inflammation, oxidative stress, nutritional deficiencies and certain endocrine conditions can accelerate the progression in genetically predisposed individuals.
The clinical pattern differs by sex. In men, hair loss usually starts with a receding hairline and thinning at the vertex (crown), following the Hamilton-Norwood scale. In women, the typical presentation is diffuse thinning over the central scalp with preservation of the frontal hairline, following the Ludwig scale. Recognizing the pattern early is essential, because regenerative therapies work best while viable follicles are still present and miniaturization is reversible.
Androgenetic alopecia is driven by the interaction of three factors: genetic predisposition, androgen hormones and time. Genes inherited from both parents determine how many androgen receptors are expressed in the dermal papilla of scalp follicles and how active the enzyme 5-alpha reductase is in those tissues.
Testosterone circulates in both men and women. In susceptible follicles, 5-alpha reductase converts it into dihydrotestosterone (DHT), a more potent androgen that binds androgen receptors in the hair follicle. This binding shortens the anagen (growth) phase, lengthens the telogen (resting) phase and progressively miniaturizes the follicle with each cycle. The follicle never disappears immediately, but its output becomes thinner and less pigmented.
Hormonal interplay matters beyond DHT alone. In women, the hair-promoting effect of estrogens declines after menopause, which can unmask or accelerate a previously subclinical predisposition. In both sexes, thyroid disorders, iron deficiency, vitamin D insufficiency, insulin resistance and chronic stress can amplify hair loss, even when androgenetic alopecia is the primary diagnosis.
Inflammation around the follicular unit — sometimes silent and only visible on trichoscopy — also plays a role. This microinflammation contributes to follicular fibrosis over time and helps explain why early intervention preserves more responsive follicles than waiting until the scalp is visibly bare.
Regenerative medicine for androgenetic alopecia does not create new follicles where the scalp is completely scarred or inactive. What it can do — when applied to follicles that are still alive but miniaturized — is improve the local microenvironment, prolong the anagen growth phase and support a thicker, more pigmented hair shaft. The goal is honest stabilization and gradual improvement, not the restoration of an adolescent hairline.
Platelet-rich plasma (PRP) is the most studied regenerative option. It is autologous: a small blood sample is centrifuged in-clinic to concentrate platelets and the growth factors they release (PDGF, TGF-beta, VEGF, IGF-1). These are then injected into the thinning areas of the scalp. Multiple peer-reviewed meta-analyses report statistically significant improvements in hair density and shaft thickness in patients with mild to moderate androgenetic alopecia, particularly with an initial series of three to four sessions followed by maintenance.
Mesenchymal stem cell (MSC) therapies are an emerging option. The clinical effect is mostly paracrine — the cells release trophic factors, anti-inflammatory cytokines and extracellular vesicles that modulate the follicular niche. Evidence is younger than the PRP literature, with promising pilot studies but heterogeneity in cell sources and dosing. At Regeneris we consider MSC-based protocols for selected patients with diffuse involvement or insufficient response to PRP, always within COFEPRIS-compliant sourcing and physician-led indication.
Exosomes are the newest entry in the regenerative toolkit. They are acellular nanovesicles derived from mesenchymal stem cells that carry proteins, microRNAs and lipids capable of signaling dermal papilla cells. Because no living cells are introduced, exosomes have a favorable theoretical safety profile and excellent product stability. The published literature is still maturing, but early studies suggest meaningful improvements in density when exosomes are used alone or — more commonly — combined with PRP and microneedling.
Androgenetic alopecia is a chronic, progressive condition. No regenerative therapy currently available cures it: the underlying genetic and hormonal drivers continue to act on susceptible follicles for life. What well-indicated regenerative protocols can do is slow progression, stabilize active loss and visibly improve density in patients who still have viable follicles.
The strongest results are seen in patients with Hamilton-Norwood grades II to IV (men) and Ludwig grades I to II (women) — that is, in early to moderate stages where miniaturization is reversible. Once a scalp area is completely bare and shows no follicular activity on trichoscopy, regenerative therapy alone will not regrow it; surgical hair transplantation is usually the better answer for those zones.
Outcomes are also strongly influenced by adherence to maintenance. PRP, MSC and exosome protocols generally require an initial intensive phase followed by maintenance sessions every 4 to 6 months. Patients who combine regenerative therapy with medical management (topical minoxidil, oral finasteride when indicated and corrected nutritional or hormonal deficits) consistently show the best long-term trajectories.
They solve different problems. PRP, stem cell and exosome therapies act on follicles that are alive but miniaturized — they stabilize loss and improve density in early to moderate stages. A hair transplant relocates viable follicles into completely bare zones, where regenerative therapy alone cannot grow hair. Many patients benefit from a sequential approach: regenerative therapy first to stabilize, then a transplant only for the structurally bare areas.
Revisado por Dra. Claudia Labastida · 2026-05-18
Most PRP protocols start with three to four sessions spaced 4 to 6 weeks apart, followed by maintenance every 4 to 6 months. Exosome and stem cell protocols typically need fewer sessions but follow a similar maintenance rhythm. Realistic visual changes are usually evident between months three and six, with photographic and trichoscopic comparison at every checkpoint.
Revisado por Dra. Claudia Labastida · 2026-05-18
We apply topical anesthesia and very fine needles, so most patients describe the sensation as a series of small pinches rather than true pain. Cooling devices and slow infusion further reduce discomfort. Downtime is minimal: mild redness or tenderness for 24 hours and specific instructions about washing, sun exposure and exercise. Most patients return to work the same day.
Revisado por Dra. Claudia Labastida · 2026-05-18
Cost depends on the protocol (PRP, exosomes, MSC, combined), the number of sessions and whether microneedling is added. We are transparent about pricing during the medical consultation, where we present a written plan with the total investment for the initial series and the expected maintenance schedule. We deliberately do not publish blanket prices online because each plan is personalized.
Revisado por Dra. Claudia Labastida · 2026-05-18
The hair cycle does not respond overnight. Early reductions in shedding can appear within 4 to 8 weeks. Visible improvements in density and shaft thickness are typically appreciated between months three and six, and continue to evolve up to 9 to 12 months after the initial series. Standardized photography and trichoscopy at each visit help measure progress objectively.
Revisado por Dra. Claudia Labastida · 2026-05-18
Yes. Regenerative therapies are validated for both Hamilton-Norwood (male pattern) and Ludwig (female pattern) presentations. In women, we also rule out and treat associated factors such as iron deficiency, thyroid dysfunction, vitamin D insufficiency and polycystic ovary syndrome, which can amplify hair loss even when the underlying diagnosis is androgenetic alopecia.
Revisado por Dra. Claudia Labastida · 2026-05-18
Regeneris Therapy operates under a COFEPRIS aviso de funcionamiento and only uses biologics processed in licensed Mexican laboratories with traceability from source to application. The procedures are outpatient, performed by physicians, with documented safety profiles in peer-reviewed literature. We coordinate the entire experience — from clinical evaluation to follow-up — for both local and international patients in Cancún.
Revisado por Dra. Claudia Labastida · 2026-05-18
In most cases yes — and combination tends to outperform monotherapy. Topical minoxidil and oral finasteride act through different mechanisms than regenerative biologics, so they complement each other. Any pharmacological prescription is decided by our physicians after reviewing your medical history, current medications and personal preferences.
Revisado por Dra. Claudia Labastida · 2026-05-18
An honest comparison of PRP, stem cells, and exosomes for androgenetic alopecia: clinical evidence, ideal candidates, and the Regeneris protocol.
A complete guide to platelet-rich plasma (PRP) therapy: how it works, clinical indications, what to expect, and why it is a popular option in regenerative medicine.
Knee osteoarthritis (gonarthrosis, ICD-10 M17) is the progressive wear of the cartilage that covers the femur, tibia and patella. At Regeneris Therapy we combine current clinical evidence and regenerative medicine to reduce pain, improve mobility and, in selected cases, postpone or avoid total knee replacement.
Learn about Knee OsteoarthritisFibromyalgia is real, medical and deserves an honest approach. At Regeneris Therapy we combine regenerative medicine, IV therapy and an integrative protocol to help you recover energy, sleep and quality of life — always alongside your rheumatologist.
Learn about Fibromyalgia in Cancún: Symptoms, Causes and Regenerative OptionsLupus is a serious, lifelong autoimmune disease. The cornerstone of care is a rheumatologist and disease-modifying medication — regenerative protocols are only an investigational adjunct that we coordinate around your treating physician, never a replacement.
Learn about Systemic Lupus Erythematosus in Cancún: Care and Regenerative AdjunctsNext step
Every plan at Regeneris starts with a physician-led trichoscopic evaluation: we map the pattern, rule out associated causes and recommend the protocol — regenerative, medical, surgical or combined — that gives you the best realistic outcome. Book your consultation and bring your questions; we will give you straight answers.